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ABSTRACT
Objectives: The objectives of this study were to study the efficacy of diode laser prostatectomy in patients infected with benign prostatic enlargement.
Methods: A total of 62 men were included in our prospective clinical study from August 2017 to January 2018. The size of their prostates (ml) was 
ranged from 38 to 65, digital rectal examination for all patients was revealed the features of benign prostatic enlargement, prostate-specific antigen 
was ranged from 0.3 to 14 ng/ml, underwent laser prostatectomy (Diode laser).
Results: The study included 62 men with 67.82±7.57 years. After the operation, the median maximum flow rate (Qmax) was increased 11–22 ml/s 
and the increment was highly significant (p<0.001), and median international prostate symptom score was highly significantly reduced from 19 to 
10 (p<0.001). In addition, median residual volume was highly significantly reduced from 169.5 to 77 ml (p<0.001). Mean duration of operation was 
67.82±7.57 min. The duration of catheterization with a mean of 1.16±0.45 days. Most patients required only 1 day of hospital stay postoperatively. No 
one developed post-operative bleeding, erectile dysfunction was reported in a single patient (1.6%), urinary incontinence in one patient (1.6%), and 
urinary tract infection was the most frequent post-operative complication being reported in 11.3%.
Conclusion: Diode laser for the treatment of prostate is easily applicable, cheap and provides good ablation with low morbidity.
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INTRODUCTION
The benign prostatic hyperplasia (BPH) is one of the important causes 
of dysfunction of the urinary tract in elderly males, and the prevalence 
increases with increasing age [1]. The treatment includes medical 
and surgical measures. The surgical measures have been included in 
patients with moderate-to-severe symptoms that do not respond to 
medical therapy or complicated BPH by stone, diverticulum, or repeated 
or recurrent infections.
Transurethral resection of the prostate (TURP) has been a standard 
surgical procedure for treatment of BPH for many years, but it has 
morbidity in the form of bleeding, retrograde ejaculation, urinary 
incontinence, and dilutional hyponatremia [2]. These symptoms are 
improved by laser, but it has significant complications in the form of 
prolonged irritative symptoms and urination of sloughed tissue after 
the operation [2,3]. Different types of laser are available (holmium [Ho], 
potassium titanyl phosphate [KTP], thulium, and diode laser) for the 
surgical treatment of BPH [4,5].
This development of laser begun in serious by Einstein in 1917, 
when projected the concept of tremendously focused light beams 
and stimulated emission of microwaves [6]. The short form for light 
amplification by the stimulated emission of radiation (LASER) was 
coined in 1957 by Maiman who produced the first visible light laser in 
the 1960s [7]. The frequent of LASER is determined by active medium, 
and the media may stimulate to LASER use in different waves; however, 
one wavelength is usually most favorable for this reason. In a search for 
prospective therapeutic methods for BPH that would be associated with 
less morbidity than TURP, the neodymium-doped yttrium aluminum 
garnet (Nd: YAG) LASER was introduced for LASER ablation [8]. The 
residual necrotic tissue caused bladder outlet obstruction and related 
symptoms for several weeks after treatment.
The lack of instantaneous tissue ablation combined with good 
hemostasis was eliminated at the time the KTP laser (60 W) was 
clinically introduced for the treatment of vaporization of hyperplastic 
obstructive prostate tissue [9,10]. Vaporization with the 532 nm KTP 
laser is broadly accepted, due to the short learning curve due to the 
simplicity of the technique [11,12]. However, effectiveness decreases 
as volume (>70 ml) or prostate-specific antigen (PSA) (>6 ng/ml) 
increases [12]. What is more, most fibers lose 80% of power during the 
procedure [13].
Large glands may necessitate more than one fiber, due to the restricted 
lifespan, i.e., 275,000 J. As in recent times proposed alternative, diode 
LASER (980 nm, 150 W) offers a high degree of absorption in water and 
hemoglobin and it is considered to be the best in terms of hemostatic 
properties and rapid ablation rate; it has tissue penetration rate about 
5 mm but is less acceptable due to post-operative dysuria, pain, and 
storage urinary symptoms [14].
METHODS
A total of 62 men were included in our prospective clinical study 
throughout 5 months, from August 2017 to January 2018 (patient 
consent was taken). Their ages range from 54 to 88 years, the following 
parameters were included for each patient: Maximal flow rates 
(ml/s) calculated by uroflowmetry, international prostate symptom 
score (IPSS), and residual volume (ml); size of their prostates (ml) 
by abdominal ultrasound was ranged from 38 to 65, digital rectal 
examination (DRE) for all patients was revealed features of benign 
prostatic enlargement, PSA was ranged from 0.3 to 14 ng/ml, and 
underwent laser prostatectomy (980 nm, side-fire fiber, 150 W, 
Diode laser, biolitec Germany), under spinal anesthesia preceded by 
prophylactic ceftriaxone antibiotic, by laser cystoscopy-21 French with 
normal saline irrigation.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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RESULTS
The study included 62 men with a mean age of 67.82±7.57 years and 
an age range of 54–88 years. After the operation, the median maximum 
flow rate was increased from 11 ml/s to 22 ml/s and the increment was 
highly significant (p<0.001), and median IPSS was highly significantly 
reduced from 19 to 10 (p<0.001). In addition, median residual volume 
was highly significantly reduced from 169.5 to 77 ml (p<0.001), as 
shown in Table 1 and Fig. 1.
Mean duration of operation was 67.82±7.57 min and ranged from 
44 to 80 min. The duration of catheterization varied from 1 to 3 days with 
a mean of 1.16±0.45 days. Most patients (91.9%) required only 1 day 
of hospital stay postoperatively, three of them (4.8%) leave hospital on 
the same day of operation, whereas 2 of them (3.2%) stayed for 2 days. 
No one developed post-operative bleeding, erectile dysfunction was 
reported in a single patient (1.6%), urinary incontinence in one patient 
(1.6%) and urinary tract infection was the most frequent post-operative 
complication being reported in 7 patients (11.3%) as shown in Table 2.
Statistical analysis
Data were analyzed using Statistical Package for the Social Sciences 
(SPSS) version 22 and Microsoft Office Excel 2010. Numeric variables 
were tested for normality distribution using Kolmogorov–Smirnov 
test and presented as the median and interquartile range. p≤0.05 was 
considered to be statistically significant. For the purpose of comparison, 
Wilcoxon Sign was used.
DISCUSSION
The treatment of BPH is done by medical and surgical options. The 
medical treatment is informed of α-blockers and 5-α-reductase 
inhibitors. The surgical treatment includes open surgery, TURP, and 
other minimally invasive procedures. Open surgical removal has been 
used when medical therapy is failed or there is complicated BPH by 
stone, diverticulum, or repeated infections. Open surgery is aggressive 
and followed by many complications (wound, pain, bleeding, and 
erectile dysfunction) but can be done for the large-sized prostate. 
TURP is considered the gold standard surgical option for adenoma 
˂60 ml because of better outcome regarding Qmax, IPSS, and post-
void residual (PVR), but it has mortality 0.3% and morbidity 19% 
(TUR syndrome, blood transfusion due to bleeding - 20 g/min [15], 
and erectile dysfunction - 15%) [16]. To decrease the complications of 
TURP, the LASER developed to resolve some problems. Many types of 
laser have been used to treat BPH. Nd:YAG LASER (1064 nm) has deep 
coagulation ability but poor absorption and poor vaporization leading 
the larger expelling of necrotic tissue that limit the use of Nd:YAG 
LASER (1064 nm) in BPH treatment [17]. Ho:YAG LASER (2140 nm) 
has the good absorptive ability by prostatic tissue, good vaporization, 
less necrotic tissue leading to good results comparable to TURP, but it 
has long learning curve [18]. KTP LASER (532 nm) has good prostatic 
tissue vaporization, good hemostasis, less coagulation depth leading 
to less expelling of necrotic tissue, and also the lack of tissue retrieval. 
Diode LASER (980 nm) has many advantages (small box size) [19], 
absorbed by hemoglobin and water, and this give rapid vaporization 
and hemostasis, tissue ablation shortening the operative time, cheaper 
than KTP or Holmium laser enucleation of the prostate but also the lack 
of tissue retrieval.
Diode LASER avoids complications of TURP and open surgery, and at the 
same times, it has many advantages (easily applicable, cheap, and good 
ablation ability - 10 g/min) and less blood loss - 0.2 g/min 100-fold 
less than TURP as Wendt and his colleagues said [20-22]. Many studies 
mentioned changes toward better results regarding urinary parameters 
after diode laser prostatectomy like Chen, Chiang, RusZat, and Erol et al. 
regarding IPSS (55–75%), Qmax (5–14%), and PVR (58–87%). Our study 
selected 62-year-old men who have BPH sized 38–65 ml, PSA˂14 ng/ml, 
and features of benign adenoma by DRE. Diode prostatectomy has been 
done for theirs. The changes in outcome have been seen regarding mean 
Qmax from 11 to 22 ml/s, mean IPSS from 19 to 10, and mean PVR from 
169.5 to 77 ml with p˂0.001 which is highly significant compared with 
other studies. The mean time of operation was 67.8 min, comparable to 
Table 1: Parameters before and after operation
Characteristic Pre-operative Post-operative p*
Median IQR Median IQR
Maximal flow rate (ml/s) 11.00 6.00 22.00 6.00 <0.001 HS
IPSS 19.00 9.25 10.00 7.25 <0.001 HS
Residual urine volume (ml) 169.50 77.00 33.00 30.00 <0.001 HS
IQR: Interquartile range; HS: highly significant; IPSS: International prostate symptom score; *Wilcoxon test
Fig. 1: Parameters before and after operation (a) Median 
maximum flow rate, (b) Median international prostate symptom 
score, (c) Median residual volume
cba
Table 2: Operative and post-operative events
Characteristic Value
Duration of procedure (min); mean±SD (range) 60.45±8.84 (44–80)
Duration of urinary catheter (day); mean±SD (range) 1.16±0.45 (1–3)
Hospital stay (day); mean±SD (range) 0.98±0.28
None, n (%) 3 (4.8)
For 1 day, n (%) 57 (91.9)
For 2 days, n (%) 2 (3.2)
Post-operative bleeding; n (%) 0 (0)
Erectile dysfunction; n (%) 1 (1.6)
Urinary incontinence; n (%) 1 (1.6)
Urinary tract infection; n (%) 7 (11.3)
SD: Standard deviation
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TURP or open surgery. The mean duration of the urinary catheter was 
1.16 day, and this is less than TURP or open surgery. Hospital stay is 
1 day, and this is good, no post-operative bleeding. Erectile dysfunction 
after the procedure only 1.6%. Urinary tract infections are the main 
problem because of necrotic tissue.
No mortality, very low morbidity with good outcome compared to other 
LASER procedures, and TURP make this procedure more preferable in 
spite of the standardization of TURP.
CONCLUSION
Diode LASER for the treatment of prostate is easily applicable, cheap 
and provides good ablation with low blood loss.
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